#Anixa Biosciences #San Jose #Australia #Patent #Breast Cancer Vaccine

Anixa Biosciences Grants First Patent in Australia for Breast Cancer Vaccine

Anixa Biosciences, Inc., a clinical-stage biotechnology firm listed on NASDAQ (ANIX), is making strides in the battle against breast cancer. Recently, the company announced that the Australian Intellectual Property office granted them a crucial patent for their innovative breast cancer vaccine technology, further expanding their global intellectual property protection until 2040. This strategic move underscores Anixa's commitment to addressing an urgent health issue, as there are currently no available vaccines around the globe designed specifically to prevent breast cancer.

Overview of the Patent Award

The newly awarded Patent Number 2020221280, revolves around the unique composition of the breast cancer vaccine, which has been exclusively licensed from the Cleveland Clinic. The patent is titled "Vaccine Adjuvants and Formulations,” co-invented by the renowned Dr. Justin Johnson and the late Dr. Vincent Tuohy. This patent not only solidifies Anixa's innovative approach to cancer treatment but also signifies a reinforcement of the company's already extensive patent portfolio, which includes patents filed in key markets like Europe, China, and Japan.

With the increasing incidence of breast cancer globally, this patent is poised to position Anixa as a leader in cancer immunotherapy. The patent's international coverage facilitates Anixa's capability to establish future regulatory approvals, strategic collaborations, and commercialization prospects.

Clinical Trial Success and Future Directions

The vaccine technology's foundation lies in a Phase 1 clinical trial conducted at the Cleveland Clinic, which was notably funded by the U.S. Department of Defense. The trial results were promising, demonstrating that the vaccine met major primary endpoints, showcased a favorable safety profile, and induced immune responses in over 74% of participants. Such encouraging outcomes validate the ongoing development of this breast cancer vaccine.

Dr. Amit Kumar, the Chairman and CEO of Anixa Biosciences, emphasized the significance of this patent, stating, "This newly issued patent strengthens the global foundation we are building for our breast cancer vaccine." As clinical development continues in the United States, Anixa is eyeing global opportunities, ready to potentially partner with larger pharmaceutical firms for worldwide commercialization of their breakthrough treatment.

The Significance of the Vaccine

Breast cancer is recognized as the most frequently diagnosed cancer among women worldwide. Despite advancements in screening and treatment, no preventive vaccines exist. Anixa's approach focuses on immunizing against human α-lactalbumin, a protein that has been discovered to be aberrantly expressed in specific breast cancer cases. This innovative strategy seeks to prepare the immune system to thwart tumor formation without damaging healthy tissue, which is especially crucial for aggressive forms of breast cancer like triple-negative breast cancer.

Anixa's vaccine could revolutionize how breast cancer is approached within the medical community, presenting one of the first preventive strategies targeting this significant health issue. By solidifying its global patent estate, Anixa is ambitiously establishing the groundwork for future international development efforts.

About Anixa Biosciences

Founded with a focus on cancer treatment and prevention, Anixa Biosciences has developed a rich therapeutic portfolio, including their ovarian cancer immunotherapy, which is under development in collaboration with the Moffitt Cancer Center. Their unique CAR-T technology, designed to battle various cancers, is aimed at harnessing the body's immune response. In addition to the breast cancer vaccine, Anixa is developing further vaccine and immunotherapy options targeting a wide range of challenging malignancies.

The breadth of Anixa's innovative capabilities, combined with their established research partnerships, makes them a key player in the rapidly evolving biopharmaceutical industry. With growing interest in immunotherapy, Anixa is demonstrating its potential to transform cancer prevention and treatment approaches.

To learn more about Anixa’s groundbreaking work, visit Anixa Biosciences and follow them on their social media channels.